Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling

(2020) J. L. Woodhead et al.   PHARMACEUTICAL RESEARCH

Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling

(2020) Caroline R. Sussman et al.   CELLULAR SIGNALLING

Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2–Dependent Mechanism in Polycystic Kidney Disease

(2020) Nidhi Dwivedi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease

(2019) Jacob A. Torres et al.   JOURNAL OF CLINICAL INVESTIGATION

Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells

(2019) Annarita Di Mise et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

ADPKD current management and ongoing trials

(2019) Francesca Testa et al.   JOURNAL OF NEPHROLOGY

CaSR signaling down-regulates AQP2 expression via a novel microRNA pathway in pendrin and NaCl cotransporter knockout mice

(2018) Marianna Ranieri et al.   FASEB JOURNAL

Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells

(2018) Annarita Di Mise et al.   Scientific Reports

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

(2018) Fouad T. Chebib et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis

(2018) Giuseppe Vezzoli et al.   Urolithiasis

External Ca 2+ regulates polycystin-2 (TRPP2) cation currents in LLC-PK1 renal epithelial cells

(2017) Xiao Qing Dai et al.   EXPERIMENTAL CELL RESEARCH

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

(2017) Vicente E Torres et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

(2017) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016

(2016) Fouad T. Chebib et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Localization and function of the renal calcium-sensing receptor

(2016) Daniela Riccardi et al.   Nature Reviews Nephrology

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

(2016) Jeffrey L. Woodhead et al.   TOXICOLOGICAL SCIENCES

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

(2015) Paul B. Watkins et al.   DRUG SAFETY

Tolvaptan plus Pasireotide Shows Enhanced Efficacy in a PKD1 Model

(2014) K. Hopp et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

(2014) E. M. Spithoven et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase

(2013) Nutthapoom Pathomthongtaweechai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy

(2013) Isaline Rowe et al.   NATURE MEDICINE

Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity

(2012) Katharina Hopp et al.   JOURNAL OF CLINICAL INVESTIGATION

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calcimimetics inhibit renal pathology in rodent nephronophthisis

(2011) Neal X. Chen et al.   KIDNEY INTERNATIONAL

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis

(2011) V. Takiar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Calcimimetic Inhibits Late-Stage Cyst Growth in ADPKD

(2009) V. H. Gattone et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease

(2008) X. Wang et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Autosomal Dominant Polycystic Kidney Disease

(2008) Jared J. Grantham   NEW ENGLAND JOURNAL OF MEDICINE